Literature DB >> 20826448

Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.

Jacquelyn A Brown1, Ryan J Emnett, Crystal R White, Carla M Yuede, Sara B Conyers, Karen L O'Malley, David F Wozniak, David H Gutmann.   

Abstract

Learning and behavioral abnormalities are among the most common clinical problems in children with the neurofibromatosis-1 (NF1) inherited cancer syndrome. Recent studies using Nf1 genetically engineered mice (GEM) have been instructive for partly elucidating the cellular and molecular defects underlying these cognitive deficits; however, no current model has shed light on the more frequently encountered attention system abnormalities seen in children with NF1. Using an Nf1 optic glioma (OPG) GEM model, we report novel defects in non-selective and selective attention without an accompanying hyperactivity phenotype. Specifically, Nf1 OPG mice exhibit reduced rearing in response to novel objects and environmental stimuli. Similar to children with NF1, the attention system dysfunction in these mice is reversed by treatment with methylphenidate (MPH), suggesting a defect in brain catecholamine homeostasis. We further demonstrate that this attention system abnormality is the consequence of reduced dopamine (DA) levels in the striatum, which is normalized following either MPH or l-dopa administration. The reduction in striatal DA levels in Nf1 OPG mice is associated with reduced striatal expression of tyrosine hydroxylase, the rate-limited enzyme in DA synthesis, without any associated dopaminergic cell loss in the substantia nigra. Moreover, we demonstrate a cell-autonomous defect in Nf1+/- dopaminergic neuron growth cone areas and neurite extension in vitro, which results in decreased dopaminergic cell projections to the striatum in Nf1 OPG mice in vivo. Collectively, these data establish abnormal DA homeostasis as the primary biochemical defect underlying the attention system dysfunction in Nf1 GEM relevant to children with NF1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826448      PMCID: PMC2957316          DOI: 10.1093/hmg/ddq382

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  44 in total

1.  Gypenosides protects dopaminergic neurons in primary culture against MPP(+)-induced oxidative injury.

Authors:  Peng Wang; Le Niu; Xiao-Dong Guo; Li Gao; Wei-Xin Li; Dong Jia; Xue-Lian Wang; Lian-Ting Ma; Guo-Dong Gao
Journal:  Brain Res Bull       Date:  2010-07-06       Impact factor: 4.077

2.  Evidence for neurogenesis in the adult mammalian substantia nigra.

Authors:  Ming Zhao; Stefan Momma; Kioumars Delfani; Marie Carlen; Robert M Cassidy; Clas B Johansson; Hjalmar Brismar; Oleg Shupliakov; Jonas Frisen; Ann Marie Janson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-05       Impact factor: 11.205

3.  Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.

Authors:  Biljana Georgievska; Deniz Kirik; Anders Björklund
Journal:  Exp Neurol       Date:  2002-10       Impact factor: 5.330

4.  Neurofibromatosis type 1 (Recklinghausen's disease). Neurologic and cognitive assessment with sibling controls.

Authors:  R Eldridge; M B Denckla; E Bien; S Myers; M I Kaiser-Kupfer; A Pikus; S L Schlesinger; D M Parry; J M Dambrosia; M A Zasloff
Journal:  Am J Dis Child       Date:  1989-07

Review 5.  Neurocognitive dysfunction in children with neurofibromatosis type 1.

Authors:  Tena L Rosser; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

6.  Visual-spatial performance deficits in children with neurofibromatosis type-1.

Authors:  Gregory W Schrimsher; Rebecca L Billingsley; John M Slopis; Bartlett D Moore
Journal:  Am J Med Genet A       Date:  2003-07-30       Impact factor: 2.802

7.  Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.

Authors:  Michaela Livia Bajenaru; Yuan Zhu; Nicolé M Hedrick; Jessica Donahoe; Luis F Parada; David H Gutmann
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Social skills of children with neurofibromatosis type 1.

Authors:  Belinda Barton; Kathryn North
Journal:  Dev Med Child Neurol       Date:  2004-08       Impact factor: 5.449

9.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.

Authors:  C I Brannan; A S Perkins; K S Vogel; N Ratner; M L Nordlund; S W Reid; A M Buchberg; N A Jenkins; L F Parada; N G Copeland
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

10.  Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.

Authors:  M Livia Bajenaru; M Rosario Hernandez; Arie Perry; Yuan Zhu; Luis F Parada; Joel R Garbow; David H Gutmann
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  55 in total

1.  Risky Decision Making in Neurofibromatosis Type 1: An Exploratory Study.

Authors:  Rachel K Jonas; EunJi Roh; Caroline A Montojo; Laura A Pacheco; Tena Rosser; Alcino J Silva; Carrie E Bearden
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-03

Review 2.  The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.

Authors:  Maria T Acosta; Carrie E Bearden; F Xavier Castellanos; Xavier F Castellanos; Laurie Cutting; Ype Elgersma; Gerard Gioia; David H Gutmann; Yong-Seok Lee; Eric Legius; Maximillian Muenke; Kathryn North; Luis F Parada; Nancy Ratner; Kim Hunter-Schaedle; Alcino J Silva
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

3.  Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

Authors:  Thijs van der Vaart; André B Rietman; Ellen Plasschaert; Eric Legius; Ype Elgersma; Henriëtte A Moll
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

4.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

5.  Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation.

Authors:  Corina Anastasaki; Nicholas Rensing; Kevin J Johnson; Michael Wong; David H Gutmann
Journal:  J Sleep Res       Date:  2019-01-04       Impact factor: 3.981

6.  Using animal models to evaluate the functional consequences of anesthesia during early neurodevelopment.

Authors:  Susan E Maloney; Catherine E Creeley; Richard E Hartman; Carla M Yuede; Charles F Zorumski; Vesna Jevtovic-Todorovic; Krikor Dikranian; Kevin K Noguchi; Nuri B Farber; David F Wozniak
Journal:  Neurobiol Learn Mem       Date:  2018-03-14       Impact factor: 2.877

7.  Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.

Authors:  Kelly A Diggs-Andrews; Kazuhiro Tokuda; Yukitoshi Izumi; Charles F Zorumski; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 9.  Dopaminergic dysfunction in neurodevelopmental disorders: recent advances and synergistic technologies to aid basic research.

Authors:  J Elliott Robinson; Viviana Gradinaru
Journal:  Curr Opin Neurobiol       Date:  2017-08-30       Impact factor: 6.627

Review 10.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.